BEVERLY HILLS, Calif.,
March 20, 2014 /PRNewswire/
-- Life Stem Genetics, Inc. (LIFS), an emerging innovator in
the advancement of Adult Stem Cell therapies, today announced the
appointment of Dr. Vino Padayachee, a well-known family
physician/anesthetist, as Director and Chairman of the Board of
Directors of the company. Dr. Padayachee has been actively involved
in the Saskatchewan Medical Association as a member of the
Representative Assembly, the Board of Directors, and the executive.
He served as Chief of Staff of St.
Joseph's Hospital in Estevan,
Saskatchewan, from 1998 to 2009, as Chief of Staff of South
East Health District from 1999 to 2004, and as Chief of Staff of
Sun Country Health Region from 2004 to 2008. He was the first
Clinical Chair for the Health Quality Council Chronic Disease
Management Collaborative from 2005 to 2007. Dr. Padayachee served
as President of the Saskatchewan Medical Association in 2006-2007
and as CEO of the Saskatchewan Medical Association from 2011 to
February 2014.
Dr. Padayachee commented, "Adult Stem Cells, particularly
mesenchymal cells which can differentiate into a variety of
tissues, hold immense promise in the treatment of a wide range of
conditions. Many patients, including those with autoimmune diseases
such as multiple sclerosis, type 1 diabetes, and rheumatoid
arthritis, as well as patients with heart disease, spinal cord
trauma, and orthopedic injuries should see benefits from this
promising new form of therapy. Life Stem's focus on mesenchymal
cell harvesting and the advanced medical applications therein
represent a robust market segment that should continue to produce
leading-edge advancements in these critical treatment areas over
the coming years and decades. I am ecstatic to be joining Life Stem
Genetics as Director and Chairman of the Board of Directors, and I
look forward to working with the company's dedicated personnel and
advisors on the continued advancement of Adult Stem Cell therapies
for the benefit of all."
Gloria Simov, president and CEO
of Life Stem Genetics, added, "Dr. Padayachee, in his position as
President and CEO of the Saskatchewan Medical Association,
developed contacts with leaders in the health/medical field
throughout North America. Dr.
Paydayachee's demonstrated leadership skills together with his
impressive medical and administrative background provides our
company with a powerful new voice in advancing the potential of
Adult Stem Cell therapies. Dr. Padayachee exudes a keen
interest in the areas of quality of health improvement where
advanced Adult Stem Cell (ASC) therapies have the potential to
revolutionize treatment options for patients. We are extremely
excited about his forthcoming contributions to our company as
Director and Chairman of the Board of Directors. Regenerative
medicine is projected to be a $35
billion industry by 2018. We are in the process of updating
our corporate growth agenda for 2014 to enable us to play a
significant part in that industry and will be presenting that
update to our shareholders and the investing community in the near
future."
About Dr. Vino Padayachee
Dr. Padayachee began his medical career in South Africa, where he obtained his medical
degree from the University of Natal. After graduating, he worked in
teaching hospitals attached to the university where he developed a
broad range of expertise including pediatrics, surgery and trauma,
and obstetrics, including special training in cardiology. During
that time, he managed a coronary care unit and obtained a diploma
in anesthesiology. In 1992, Dr. Padayachee moved to Canada, along with his wife, Dr. Diane Naidu, to settle in Estevan, Saskatchewan, where he practiced as a
general practitioner anesthetist. Dr. Padayachee has a dedicated
interest in quality improvement, and, in response to the increasing
prevalence of asthma in southern Saskatchewan, he helped establish an asthma
clinic in 2003 and was also involved with the Heart to Heart
Coronary Heart Disease Secondary Prevention Program in Estevan. Dr. Padayachee served as chief of
staff of St. Joseph's Hospital in
Estevan, Saskatchewan, and the Sun
Country Health Region. He also served as clinical chair for the
Health Quality Council Chronic Disease Management Collaborative
from 2005 to 2007. Dr. Padayachee has been actively involved in the
Saskatchewan Medical Association as a member of the Representative
Authority, the Board of Directors, and the executive. Dr.
Padayachee served as President of the Saskatchewan Medical
Association from 2006 to 2007 and as CEO from 2011 to February 2014.
About Life Stem Genetics
Life Stem Genetics, symbol: LIFS, is a fully reporting, audited
public company. LIFS is a progressive healthcare company focused on
Adult Stem Cell (ASC) healing therapies and stem cell related
products. Stem cells have been utilized in the successful treatment
of a variety of ailments. Today, advanced ASC therapies are being
offered to patients as an efficient and painless alternative
treatment for a wide range of ailments including, but not limited
to, orthopedic injuries, neurological disorders such as Parkinson's
and Alzheimer's, cancer, arthritis, diabetes, multiple sclerosis,
as well as age management. Adult Stem Cell therapies are
experiencing some of the best results in the health care industry
in helping to repair or reprogram damaged or diseased tissues and
organs. ASC treatments have been performed on some of the top names
in PGA golf, NFL football, NBA basketball, and Major League
Baseball. LSG will offer treatments through a series of affiliate
doctors and medical clinics in the U.S., Canada, South
America, Europe, and the
Middle East.
Contrarian Press, an established publisher, has been engaged by
Life Stem Genetics to assist with patient generation and those who
may be interested in learning more about the company and its
securities. Updated disclaimer and disclosure information is
available at the publisher's website and at the following
link: http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
This press release contains "forward-looking statements" within
the meaning of the "safe-harbor" provisions of the Private
Securities Litigation Reform Act of 1995 that are not historical
facts. These statements can be identified by the use of
forward-looking terminology such as "believe," "expect," "may",
"could", "estimates", "will," "should," "project,"
"plan," "seek," "intend," or "anticipate" or the negative thereof
or comparable terminology, and include discussions of strategy, and
statements about industry trends and the Company's future
performance, operations, and products. Such statements involve
known and unknown risks, uncertainties and other factors that could
cause the Company's actual results to differ materially from the
results expressed or implied by such statements. Such risks and
uncertainties include, without limitation, market acceptance of the
Company's stem cell therapy treatment program; the Company's
compliance with applicable statutes and regulations: the Company's
reliance on third-party contractors to provide suitable treatment
facilities; the Company's ability to expand its network of
participating clinics and doctors; the Company's ability to develop
an effective marketing strategy; the Company's ability to control
and reduce advertising and marketing costs; the Company's ability
to develop and increase awareness of its brand; the Company's
ability to protect its trademarks; and the success of the Company's
marketing focus to patients, doctors and clinics. For a discussion
of these and other risks and uncertainties see "Risk Factors" and
"Description of Business" in the Company's public filings with the
SEC. Although the Company believes that the expectations reflected
in such forward-looking statements are reasonable, there can be no
assurance that such expectations will prove to be correct. The
Company has no obligation to update the forward-looking information
contained in this press release.
SOURCE Life Stem Genetics, Inc.